Recombinant%20Human%20Hyaluronidase
Showing 26 - 50 of >10,000
AL Amyloidosis Trial (procedure, drug, other)
Not yet recruiting
- AL Amyloidosis
- Autologous Hematopoietic Stem Cell Transplantation
- +15 more
- (no location specified)
Aug 28, 2023
Health, Subjective Trial in Seoul (BMI2004, 0.9% NaCl)
Completed
- Health, Subjective
- BMI2004
- 0.9% NaCl
-
Seoul, Heukseok-ro, Dongjak-gu, Korea, Republic ofChung-Ang University Hospital
Jun 26, 2023
Exposure During Pregnancy Trial in Worldwide (A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or
Completed
- Exposure During Pregnancy
- A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment
- HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]
-
Durham, North Carolina
- +7 more
Apr 2, 2021
Primary Immunodeficiency Diseases (PID) Trial in United States (SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC,
Completed
- Primary Immunodeficiency Diseases (PID)
- SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)
- +2 more
-
Cypress, California
- +10 more
Apr 30, 2021
Hepatic Ascites Trial in Guangdong (Recombinant Human Serum Albumin, Human serum albumin)
Not yet recruiting
- Hepatic Ascites
- Recombinant Human Serum Albumin
- Human serum albumin
-
Guangdong, Shenzhen, ChinaShenzhen Protgen Ltd
May 5, 2023
Advanced Mucosal Melanoma Trial (Envafolimab combined with recombinant human endostatin and first-line chemo)
Not yet recruiting
- Advanced Mucosal Melanoma
- Envafolimab combined with recombinant human endostatin and first-line chemotherapy
- (no location specified)
Sep 15, 2023
Malignant Melanomas Trial in Fuzhou (Recombinant Human Adenovirus Type 5 Injection)
Enrolling by invitation
- Malignant Melanomas
- Recombinant Human Adenovirus Type 5 Injection
-
Fuzhou, Fujian, ChinaFujian Cancer Hospital, Department of Internal Medicine, Ward 19
Jul 7, 2023
Nasopharyngeal Carcinoma Trial (Envafolimab and recombinant human endostatin combined with chemoradiotherapy)
Not yet recruiting
- Nasopharyngeal Carcinoma
- Envafolimab and recombinant human endostatin combined with chemoradiotherapy
- (no location specified)
Sep 23, 2023
Chronic Lymphocytic Leukemia Trial in Washington, Hackensack (Venetoclax, Rituximab, Rituximab/Hyaluronidase Human)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Venetoclax
- +2 more
-
Washington, District of Columbia
- +1 more
Mar 14, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Venetoclax
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +13 more
- Polatuzumab Vedotin
- +3 more
-
Scottsdale, Arizona
- +11 more
Aug 23, 2022
Advanced Solid Tumors Trial in Hangzhou, Shanghai (Recombinant human IL-21 oncolytic vaccinia virus injection)
Not yet recruiting
- Advanced Solid Tumors
- Recombinant human IL-21 oncolytic vaccinia virus injection
-
Hangzhou, Zhejiang, China
- +1 more
Jun 21, 2023
Norovirus Infections, Norwalk Gastroenteritis Trial (Human Norovirus Bivalent (G?.1/G?.4)Vaccine,Recombinant (Hansenula
Not yet recruiting
- Norovirus Infections
- Norwalk Gastroenteritis
- Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha)
- placebo
- (no location specified)
Jun 14, 2023
Chronic Inflammatory Demyelinating Polyradiculoneuropathy Trial in Worldwide (HYQVIA, 0.25% albumin solution with rHuPH20,
Completed
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- HYQVIA
- +2 more
-
Phoenix, Arizona
- +82 more
Feb 28, 2022
Herpes Zoster Trial (Recombinant Human Interferon a-2b Gel (After the Alteration), Recombinant Human Interferon a-2b Gel (Before
Not yet recruiting
- Herpes Zoster
- Recombinant Human Interferon α-2b Gel (After the Alteration)
- Recombinant Human Interferon α-2b Gel (Before the Alteration)
- (no location specified)
Apr 7, 2023
Viral Upper Respiratory Tract Infection Trial (recombinant human interferon ? spray)
Not yet recruiting
- Viral Upper Respiratory Tract Infection
- recombinant human interferon ω spray
- (no location specified)
May 7, 2023
Acute Gout Trial in Nanchang (rhTNFR-Fc, Triamcinolone Acetonide)
Not yet recruiting
- Acute Gout
- rhTNFR-Fc
- Triamcinolone Acetonide
-
Nanchang, Jiangxi, ChinaDepartment of Rheumatology and Clinical Immunology, Jiangxi Prov
Jun 28, 2023
Shoulder Pain, Neck Pain, Back Pain Trial in Qingdao (HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly
Completed
- Shoulder Pain
- +4 more
- HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)
-
Qingdao, Shandong, ChinaQingdao University Affiliated Hospital
Mar 1, 2023
Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage
Recruiting
- Advanced Solid Tumor
- Refractory Tumor
- Radiotherapy
- +4 more
-
Suzhou, ChinaThe Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 Trial in Houston (Pegylated Recombinant Human
Withdrawn
- Metastatic Pancreatic Adenocarcinoma
- Stage IV Pancreatic Cancer AJCC v8
- Pegylated Recombinant Human Hyaluronidase PH20
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Mar 11, 2020
Human Papillomavirus Infection Trial in Nanjing (Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus
Completed
- Human Papillomavirus Infection
- Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
- Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine
-
Nanjing, Jiangsu, ChinaCDC, Jiangsu Province
Jan 12, 2023
Hypertension, Diabetes, Blood Disease Trial in Baghdad (rhBMP-2)
Recruiting
- Hypertension
- +2 more
- rhBMP-2
-
Baghdad, Alresafa, IraqUniversity of Baghdad
Jan 31, 2023
Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease, DLBCL Trial in Kampala (Rituximab and Hyaluronidase Human,
Recruiting
- Burkitt Lymphoma
- +2 more
- Rituximab and Hyaluronidase Human
- +8 more
-
Kampala, UgandaUCI-Fred Hutch Cancer Centre
Mar 9, 2022
Primary Hepatocellular Carcinoma, Portal Vein Thrombosis Trial (Recombinant human adenovirus type 5 + TACE)
Not yet recruiting
- Primary Hepatocellular Carcinoma
- Portal Vein Thrombosis
- Recombinant human adenovirus type 5 + TACE
- (no location specified)
May 14, 2023
Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Cord Blood Transplant Recipient Trial in Houston
Recruiting
- Acute Myeloid Leukemia
- +4 more
- Recombinant Interleukin-7
-
Houston, TexasM D Anderson Cancer Center
Jan 26, 2023